Latest filing published 03 Sept 2026 for LIGAND PHARMACEUTICALS INCORPORATED, €3.7M.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew Reardon: trading record in brief
All filings by Andrew Reardon on record concern Ligand Pharmaceuticals Inc. Over a trading history stretching from 1 July 2026 to 3 September 2026, the count stands at 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 3 September 2026 with a transaction (€3.7M) in Ligand Pharmaceuticals Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Andrew Reardon
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,000 shares@ US$286.920.076% mcap57.2% of flowCommonSEC144:0001950047-26-009091
- 10,000 shares@ US$316.09100.0% of flowCommonSEC144:0001950047-26-006760
2 of 2 declarations
